Exempt Chemical Preparations Under the Controlled Substances Act

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-372]

Exempt Chemical Preparations Under the Controlled Substances Act

AGENCY:

Drug Enforcement Administration, Department of Justice.

ACTION:

Order with opportunity for comment.

SUMMARY:

The applications for exempt chemical preparations received by the Drug Enforcement Administration between July 1, 2025, and March 31, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through March 31, 2026, that were not included in previous

Federal Register

notices, and it does not affect preparations that have been previously published. This order also corrects the listing of several preparations that were published in the

Federal Register

notice on March 20, 2026.

DATES:

Comments must be submitted electronically or postmarked on or before July 20, 2026.

ADDRESSES:

Interested persons may file written comments on this order in accordance with 21 CFR 1308.23(e). The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. To ensure proper handling of comments, please reference “Docket No. DEA-372” on all correspondence, including any attachments.

•

Electronic comments:

The Drug Enforcement Administration (DEA) encourages that all comments be submitted through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or to attach a file for lengthier comments. Please go to

http://www.regulations.gov

and follow the online instructions at that site for submitting comments. Upon completion of your submission, you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on

Regulations.gov.

If you have received a comment tracking number, your comment has been successfully submitted and there is no need to resubmit the same comment.

•

Paper comments:

Paper comments that duplicate the electronic submission are not necessary and are discouraged. Should you wish to mail a comment

in lieu of

an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

•

Paperwork Reduction Act Comments:

All comments concerning collections of information under the Paperwork Reduction Act must be submitted to the Office of Information and Regulatory Affairs, OMB, Attention: Desk Officer for DOJ, Washington, DC 20503. Please state that your comment refers to Docket No. DEA-1189.

FOR FURTHER INFORMATION CONTACT:

Terrence L. Boos, Ph.D., Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (571) 362-8201.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

Please note that all comments received in response to this docket are considered part of the public record. The Drug Enforcement Administration (DEA) will make comments available for public inspection online at

http://www.regulations.gov.

Such information includes personal or business identifiers (such as name, address, state or Federal identifiers, etc.) voluntarily submitted by the commenter. Generally, all information voluntarily submitted by the commenter, unless clearly marked as Confidential Information in the method described below, will be publicly posted. Comments may be submitted anonymously. The Freedom of Information Act applies to all comments received.

Commenters submitting comments which include personal identifying information (PII), confidential, or proprietary business information that the commenter does not want made publicly available should submit two copies of the comment. One copy must be marked “CONTAINS CONFIDENTIAL INFORMATION” and should clearly identify all PII or business information the commenter does not want to be made publicly available, including any supplemental materials. DEA will review this copy, including the claimed PII and confidential business information, in its consideration of comments. The second copy should be marked “TO BE PUBLICLY POSTED” and must have all claimed confidential PII and business information already redacted. DEA will post only the redacted comment on

http://www.regulations.gov

for public inspection.

For easy reference, an electronic copy of this document and supplemental information to this proposed scheduling action are available at

http://www.regulations.gov.

Legal Authority

Section 201 of the Controlled Substances Act (CSA) (21 U.S.C. 811) authorizes the Attorney General, by regulation, to exempt from certain provisions of the CSA certain compounds, mixtures, or preparations containing a controlled substance, if he finds that such compounds, mixtures, or preparations meet the requirements detailed in 21 U.S.C. 811(g)(3)(B).

1

DEA regulations at 21 CFR 1308.23 and 1308.24 further detail the criteria by which the DEA Assistant Administrator may exempt a chemical preparation or mixture from certain provisions of the CSA. The Assistant Administrator may, pursuant to 21 CFR 1308.23(f), modify or revoke the criteria by which exemptions are granted and modify the scope of exemptions at any time.

1

This authority has been delegated from the Attorney General to the DEA Administrator by 28 CFR 0.100, and subsequently redelegated to the Deputy Assistant Administrator pursuant to 28 CFR 0.104 and Section 7 of the appendix to subpart R of part 0.

Exempt Chemical Preparation Applications Submitted Between July 1, 2025, and March 31, 2026

DEA received applications between July 1, 2025, and March 31, 2026, requesting exempt chemical preparation status detailed in 21 CFR 1308.23. This publication addresses preparations through March 31, 2026, that were not included in previous

Federal Register

notices, and it does not affect preparations that have been previously published. Additionally, this order corrects the listing of several preparations that were incorrectly listed in the previous

Federal Register

notice dated, March 20, 2026. The company name, product name, and/or form have been corrected. Pursuant to the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23, the Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart I below is intended for laboratory, industrial, educational, or special research purposes and not for general administration to a human being or animal and either: (1) contains no narcotic controlled substance and is packaged in such a form or concentration that the packaged quantity does not present any significant potential for abuse; or (2) contains either a narcotic or non-narcotic controlled substance and one or more adulterating or denaturing agents in such a manner, combination, quantity, proportion, or concentration that the preparation or mixture does not present any potential for abuse and, if the preparation or mixture contains a narcotic controlled substance, is formulated in such a manner that it incorporates methods of denaturing or other means so that the preparation or mixture is not liable to be abused or have ill effects, if abused, and so that

the narcotic substance cannot in practice be removed.

Accordingly, pursuant to 21 U.S.C. 811(g)(3)(B), 21 CFR 1308.23, and 21 CFR 1308.24, the Assistant Administrator has determined that each of the chemical preparations or mixtures generally described in Chart I below and specifically described in the application materials received by DEA is exempt, to the extent described in 21 CFR 1308.24, from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 (21 U.S.C. 822-823, 825-829, and 952-954) of the CSA, and 21 CFR 1301.74, as of the date that was provided in the approval letters to the individual requesters.

Scope of Approval

The exemptions are applicable only to the precise preparation or mixture described in the application submitted to DEA in the form(s) listed in this order and only for those above-mentioned sections of the CSA and the CFR. In accordance with 21 CFR 1308.24(h), any change in the quantitative or qualitative composition of the preparation or mixture, or change in the trade name or other designation of the preparation or mixture after the date of application requires a new application. The requirements set forth in 21 CFR 1308.24(b)-(e) apply to the exempted materials. In accordance with 21 CFR 1308.24(g), DEA may prescribe requirements other than those set forth in 21 CFR 1308.24(b)-(e) on a case-by-case basis for materials exempted in bulk quantities. Accordingly, in order to limit opportunities for diversion from the larger bulk quantities, DEA has determined that each of the exempted bulk products listed in this order may only be used in-house by the manufacturer, and may not be distributed for any purpose, or transported to other facilities.

Additional exempt chemical preparation requests received between January 1, 2026, and March 31, 2026, and not otherwise referenced in this order or in prior orders, may remain under consideration until DEA receives additional information required, pursuant to 21 CFR 1308.23(d), as detailed in separate correspondence to individual requesters. DEA's order on such requests will be communicated to the public in a future

Federal Register

publication.

DEA also notes that these exemptions are limited to exemption from only those sections of the CSA and the CFR that are specifically identified in 21 CFR 1308.24(a). All other requirements of the CSA and the CFR apply, including registration as an importer as required by 21 U.S.C. 957.

Chart I

Supplier name

Product name

Form

Application date

Cayman Chemical Company

Alprazolam (CRM) 1 mg/mL in methanol

Glass ampule: 2 mL

3/17/2026

Cayman Chemical Company

Alprazolam-d5 (CRM) 1 mg/mL in methanol

Glass ampule: 2 mL

3/17/2026

Cayman Chemical Company

Clonazepam (CRM) 1 mg/mL in acetonitrile

Glass ampule: 2 mL

3/17/2026

Cayman Chemical Company

Custom 13-Phytocannabinoid Mixture (CRM)—AIT (500 μg/mL each in Acetonitrile)

Glass ampule: 1 mL

1/19/2026

Cayman Chemical Company

Custom Phytocannabinoid Mixture 3, 1 mg/mL ea in acetonitrile

Glass ampule: 1 mL

1/29/2026

Cayman Chemical Company

Flunitrazepam (CRM) 1 mg/mL in acetonitrile

Glass ampule: 2 mL

3/17/2026

Cayman Chemical Company

Flunitrazepam (CRM) 1 mg/mL in methanol

Glass ampule: 2 mL

3/17/2026

Cayman Chemical Company

Lorazepam (CRM) 1 mg/mL in acetonitrile

Glass ampule: 2 mL

3/17/2026

Cayman Chemical Company

Lorazepam-13C2-d4 (CRM) 0.1 mg/mL in acetonitrile

Glass ampule: 2 mL

3/17/2026

Cayman Chemical Company

Lorazepam-13C2-d4 (CRM) 1 mg/mL in acetonitrile

Glass ampule: 2 mL

3/17/2026

Cayman Chemical Company

Lorazepam-d4 (CRM) 1 mg/mL in acetonitrile

Glass ampule: 2 mL

3/17/2026

Cayman Chemical Company

Methylmethcathinone Isomer Mixture 1 mg/mL in methanol

Glass ampule: 1 mL

10/1/2025

Cayman Chemical Company

Methylmethcathinone Isomer Mixture 100 μg/mL in methanol

Glass ampule: 1 mL

10/1/2025

Cayman Chemical Company

Phytocannabinoid Mixture 3 (CRM) 1 mg/mL ea in acetonitrile

Glass ampule: 1 mL

1/29/2026

Cayman Chemical Company

Δ8-THC-C9 (CRM) 1 mg/mL in acetonitrile

Glass ampule: 1 mL

10/1/2025

Cayman Chemical Company

Δ9-THC (CRM) 1 mg/mL in acetonitrile

Glass ampule: 1 mL

1/29/2026

Cayman Chemical Company

Δ9-THC (CRM) 100 μg/mL in acetonitrile

Glass ampule: 1 mL

1/29/2026

Cayman Chemical Company

Δ9-THCA-B (CRM) 1 mg/mL in acetonitrile

Glass ampule: 1 mL

10/1/2025

Cayman Chemical Company

Δ9-THCA-B (CRM) 1 mg/mL in methanol

Glass ampule: 1 mL

10/1/2025

Cayman Chemical Company

Δ9-THCA-B (CRM) 100 μg/mL in acetonitrile

Glass ampule: 1 mL

10/1/2025

Cayman Chemical Company

Δ9-THCA-B (CRM) 100 μg/mL in methanol

Glass ampule: 1 mL

10/1/2025

Cayman Chemical Company

Δ9-THCB Butanoate (CRM) 1 mg/mL in acetonitrile

Glass ampule: 1 mL

10/1/2025

Cayman Chemical Company

Δ9-THC-C9 (CRM) 1 mg/mL in acetonitrile

Glass ampule: 1 mL

10/1/2025

Cayman Chemical Company

Δ9-THC-d9 (CRM) 1 mg/mL in acetonitrile

Glass ampule: 1 mL

1/29/2026

Cayman Chemical Company

Δ9-THC-d9 (CRM) 100 μg/mL in acetonitrile

Glass ampule: 1 mL

1/29/2026

Cerilliant Corporation

Buprenorphine Related Compound A 1.0 mg/mL solvent

Glass ampule: 2 mL

1/29/2026

CPI International

Custom Cannabinoid mixture 3-0539 1000 ug/mL, 0.5 mL (ISO 17034) Z-G34-140539-01

Glass ampule: 0.5 mL

2/4/2026

CPI International

Custom Cannabinoid mixture 7-0538 1000 ug/mL, 0.5 mL (ISO 17034) Z-G34-140538-01

Glass ampule: 0.5 mL

2/4/2026

LGC—Dr. Ehrenstorfer

Custom 1-Methylamino-1-(3,4-methylenedioxyphenyl)-propane Hydrochloride 10 ug/mL in Acetonitrile

Amber ampule: 1 mL

9/24/2025

LGC—Dr. Ehrenstorfer

Custom Hormone Mixture 17762 100 ug/mL in Methanol DRE-Q60017762

Glass ampule: 5 mL

2/17/2026

LGC—Dr. Ehrenstorfer

Custom p-Hydroxycocaine Hydrochloride 100 ug/mL in Acetonitrile DRE-Q60020132

Pack: 5 x 1 mL glass ampules

3/4/2026

LGC-Lipomed

4-Methylmethcathinone HCl (Mephedrone), 1mg/ml in Methanol (as free base)

Glass ampule: 1 ml

8/5/2025

LGC-Lipomed

4-MethylmethcathinoneD3 HCl (Mephedrone) 0.1mg/ml in Methanol (as free base)

Glass Ampule: 1 ml

10/13/2025

LGC-Lipomed

Phenobarbital-D5 (side chain), 0.1 mg/ml in Methanol Prod No: LPM-PHB-1720-FA-0.1LM

Glass Ampule: 1 ml

8/12/2025

Lin-Zhi International

FEN Validation Sample Set 1

Set: 3 tubes, 10 ml each

7/18/2025

Lin-Zhi International

FEN Validation Sample Set 2

Set: 9 tubes, 10 ml each

7/18/2025

Lin-Zhi International

FEN Validation Sample Set 3

Set: 4 tubes, 30 ml each

7/18/2025

Lin-Zhi International

FEN Validation Sample Set 4

Set: 2 tubes,10 ml each

7/18/2025

Lin-Zhi International

FEN Validation Sample Set 5

Set: 52 vials, 1 ml each

7/18/2025

Lin-Zhi International

LZI Barbiturate Calibrator (Oral Fluid) Secobarbital, Cutoff Calibrator Ref# S0143b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Barbiturate Calibrator (Oral Fluid) Secobarbital, High Calibrator Ref# S0145b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Barbiturate Calibrator/Control (Oral Fluid) Secobarbital, Intermediate Calibrator/Level 2 Control Ref# S0148b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Barbiturate Calibrator/Control (Oral Fluid) Secobarbital, Low Calibrator/Level 1 Control Ref# S0147b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Benzodiazepine Calibrator (Oral Fluid) Oxazepam, Cutoff Calibrator Ref# S0133c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Benzodiazepine Calibrator (Oral Fluid) Oxazepam, High Calibrator Ref# S0135c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Benzodiazepine Calibrator/Control (Oral Fluid) Oxazepam, Intermediate Calibrator/Level 2 Control Ref# S0138c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Benzodiazepine Calibrator/Control (Oral Fluid) Oxazepam, Low Calibrator/Level 1 Control Ref# S0137c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Cocaine Metabolite Calibrator (Oral Fluid) Benzoylecgonine, Cutoff Calibrator Ref# S0034d

Dropper bottle: 5 mL

2/27/2026

Lin-Zhi International

LZI Cocaine Metabolite Calibrator (Oral Fluid) Benzoylecgonine, High Calibrator Ref# S0036d

Dropper bottle: 5 mL

2/27/2026

Lin-Zhi International

LZI Cocaine Metabolite Calibrator (Oral Fluid) Benzoylecgonine, Intermediate Calibrator Ref# S0035d

Dropper bottle: 5 mL

2/27/2026

Lin-Zhi International

LZI Cocaine Metabolite Calibrator (Oral Fluid) Benzoylecgonine, Low Calibrator Ref# S0033d

Dropper bottle: 5 mL

2/27/2026

Lin-Zhi International

LZI Cocaine Metabolite Control (Oral Fluid) Benzoylecgonine, Level 1 Control Ref# S0037d

Dropper bottle: 5 mL

2/27/2026

Lin-Zhi International

LZI Cocaine Metabolite Control (Oral Fluid) Benzoylecgonine, Level 2 Control Ref# S0038d

Dropper bottle: 5 mL

2/27/2026

Lin-Zhi International

LZI Fentanyl Calibrator (Urine) Fentanyl, Cutoff Calibrator Ref# 0993

Dropper bottle: 5 mL

2/27/2026

Lin-Zhi International

LZI Fentanyl Calibrator (Urine) Fentanyl, High Calibrator Ref# 0995

Dropper bottle: 5 mL

2/27/2026

Lin-Zhi International

LZI Fentanyl Calibrator (Urine) Fentanyl, Intermediate Calibrator Ref# 0994

Dropper bottle: 5 mL

2/27/2026

Lin-Zhi International

LZI Fentanyl Calibrator/Control (Urine) Fentanyl, Low Calibrator/Level 1 Control Ref# 0992

Dropper bottle: 5 mL

2/27/2026

Lin-Zhi International

LZI Fentanyl Control (Urine) Fentanyl, Level 2 Control Ref# 0998

Dropper bottle: 5 mL

2/27/2026

Lin-Zhi International

LZI Norfentanyl Calibrator (Urine), Norfentanyl, Cutoff Calibrator, Ref# 0563

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Norfentanyl Calibrator (Urine), Norfentanyl, High Calibrator, Ref# 0565

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Norfentanyl Calibrator (Urine), Norfentanyl, Intermediate Calibrator, Ref# 0564

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Norfentanyl Calibrator (Urine), Norfentanyl, Low Calibrator, Ref# 0562

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Norfentanyl Control (Urine), Norfentanyl, Level 1 Control, Ref# 0567

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Norfentanyl Control (Urine), Norfentanyl, Level 2 Control, Ref# 0568

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Opiate Calibrator (Oral Fluid) Morphine, Cutoff Calibrator Ref# S0023c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Opiate Calibrator (Oral Fluid) Morphine, High Calibrator Ref# S0025c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Opiate Calibrator (Oral Fluid) Morphine, Intermediate Calibrator Ref# S0024c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Opiate Calibrator (Oral Fluid) Morphine, Low Calibrator Ref# S0022c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Opiate Control (Oral Fluid) Morphine, Level 1 Control Ref# S0027c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Opiate Control (Oral Fluid) Morphine, Level 2 Control Ref# S0028c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Phencyclidine Calibrator (Oral Fluid) Phencyclidine, Cutoff Calibrator Ref# S0013c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Phencyclidine Calibrator (Oral Fluid) Phencyclidine, High Calibrator Ref# S0015c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Phencyclidine Calibrator (Oral Fluid) Phencyclidine, Intermediate Calibrator Ref# S0014c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Phencyclidine Calibrator (Oral Fluid) Phencyclidine, Low Calibrator Ref# S0012c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Phencyclidine Control (Oral Fluid) Phencyclidine, Level 1 Control Ref# S0017c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Phencyclidine Control (Oral Fluid) Phencyclidine, Level 2 Control Ref# S0018c

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Multi-Analyte DAU Calibrator Set E, Multi-Analyte, Cutoff Calibrator Ref# 0893

Dropper bottle: 15 mL

3/2/2026

Lin-Zhi International

Multi-Analyte DAU Calibrator Set E, Multi-Analyte, High Calibrator Ref# 0895

Dropper bottle: 15 mL

3/2/2026

Lin-Zhi International

Multi-Analyte DAU Calibrator Set E, Multi-Analyte, Intermediate Calibrator Ref# 0894

Dropper bottle: 15 mL

3/2/2026

Lin-Zhi International

Multi-Analyte DAU Calibrator Set E, Multi-Analyte, Level 1 Calibrator Ref# 0897

Dropper bottle: 15 mL

3/2/2026

Lin-Zhi International

Multi-Analyte DAU Calibrator Set E, Multi-Analyte, Level 2 Calibrator Ref# 0898

Dropper bottle: 15 mL

3/2/2026

Lin-Zhi International

Multi-Analyte DAU Calibrator Set E, Multi-Analyte, Low Calibrator Ref# 0892

Dropper bottle: 15 mL

3/2/2026

Lin-Zhi International

Oral Fluid 6-Acetylmorphine Calibrator 6-Acetylmorphine, Cutoff Calibrator Ref# S0293

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid 6-Acetylmorphine Calibrator 6-Acetylmorphine, High Calibrator Ref# S0295

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid 6-Acetylmorphine Calibrator 6-Acetylmorphine, Intermediate Calibrator Ref# S0294

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid 6-Acetylmorphine Calibrator/Control 6-Acetylmorphine, Low Calibrator/Level 1 Control Ref# S0292

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid 6-Acetylmorphine Control 6-Acetylmorphine, Level 2 Control Ref# S0297

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Amphetamine Calibrator Amphetamine, Cutoff Calibrator Ref# S0043b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Amphetamine Calibrator Amphetamine, High Calibrator Ref# S0045b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Amphetamine Calibrator Amphetamine, Intermediate Calibrator Ref# S0044b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Amphetamine Calibrator Amphetamine, Low Calibrator Ref# S0042b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Amphetamine Control Amphetamine, Level 1 Control Ref# S0046b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Amphetamine Control Amphetamine, Level 2 Control Ref# S0047b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Methamphetamine Calibrator Methamphetamine, Cutoff Calibrator Ref# S0053b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Methamphetamine Calibrator Methamphetamine, High Calibrator Ref# S0055b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Methamphetamine Calibrator Methamphetamine, Intermediate Calibrator Ref# S0054b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Methamphetamine Calibrator Methamphetamine, Low Calibrator Ref# S0052b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Methamphetamine Control Methamphetamine, Level 1 Control Ref# S0056b

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

Oral Fluid Methamphetamine Control Methamphetamine, Level 2 Control Ref# S0057b

Dropper bottle: 5 mL

2/26/2026

Microgenics Corporation

MAS

TM

Omni•IMMUNE

TM

Control, Level 1

Glass bottle: 5 mL

1/16/2026

Microgenics Corporation

MAS

TM

Omni•IMMUNE

TM

Control, Level 2

Glass bottle: 5 mL

1/16/2026

Microgenics Corporation

MAS

TM

Omni•IMMUNE

TM

Control, Level 3

Glass bottle: 5 mL

1/16/2026

RTI International

OF26-01

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-02

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-03

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-04

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-05

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-06

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-07

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-08

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-09

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-10

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-11

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-12

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-13

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-14

HDPE vials: 3 mL

2/17/2026

RTI International

OF26-15

HDPE vials: 3 mL

2/17/2026

The Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart II, below, is not consistent with the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23. Accordingly, the Assistant Administrator has determined that the chemical preparations or mixtures generally described in Chart II, below, and specifically described in the application materials received by DEA, are not exempt from application of any part of the CSA or from application of any part of the CFR, with regard to the requested exemption pursuant to 21 CFR 1308.23, as of the date that was provided in the determination letters to the individual requesters.

Chart II

Supplier name

Product name

Form

Application date

Lin-Zhi International

LZI Ecstasy Calibrator (Oral Fluid) MDMA, Cutoff Calibrator Ref# S0163

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Ecstasy Calibrator (Oral Fluid) MDMA, High Calibrator Ref# S0165

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Ecstasy Calibrator/Control (Oral Fluid) MDMA, Intermediate Calibrator/Level 2 Control Ref# S0168

Dropper bottle: 5 mL

2/26/2026

Lin-Zhi International

LZI Ecstasy Calibrator/Control (Oral Fluid) MDMA, Low Calibrator/Level 1 Control Ref# S0167

Dropper bottle: 5 mL

2/26/2026

Microgenics Corporation

1 mg/mL Phencyclidine

Kit: Glass bottles,10 mL, 50 mL, 100 mL, 250 mL

2/16/2026

Microgenics Corporation

5 mg/mL Benzoylecgonine

Kit: Glass bottles, 5 mL,10 mL, 50 mL, 100 mL, 250 mL

2/16/2026

Microgenics Corporation

5 mg/mL d-Methamphetamine

Kit: Glass bottles, 50 mL, 100 mL, 250 mL

2/16/2026

Microgenics Corporation

5 mg/mL Methadone Stock

Kit: Glass bottles, 25 mL, 50 mL, 100 mL, 250 mL

2/16/2026

Microgenics Corporation

5 mg/mL Morphine

Kit: Glass bottles, 50 mL, 100 mL, 250 mL, 500 mL

2/16/2026

Microgenics Corporation

Benzoylecgonine (Cocaine) Control Stock Solution 5mg/mL

Kit: Glass bottles, 5 mL,10 mL, 50 mL, 100 mL, 250 mL

2/16/2026

Microgenics Corporation

Methadone Control Stock Solution (5mg/mL)

Kit: Glass bottles, 25 mL, 50 mL, 100 mL, 250 mL

2/16/2026

Microgenics Corporation

Methamphetamine (Amphetamines) Control Stock Solution (5 mg/mL)

Kit: Glass bottles, 5 mL,10 mL, 50 mL, 100 mL, 250 mL

2/16/2026

Microgenics Corporation

Morphine (Opiate) Control Stock Solution (5 mg/mL)

Kit: Glass bottles, 10 mL, 25 mL, 50 mL, 100 mL, 250 mL, 500 mL

2/16/2026

Microgenics Corporation

PCP Control Stock Solution (1mg/mL)

Kit: Glass bottles, 10 mL, 50 mL, 100 mL

2/16/2026

Purisys, LLC

1 mg/mL D9-THC in methanol

Bottle: 50 g

2/25/2026

Restek Corporation

HC Δ9-THC Stock 50,000 μg/mL)

Glass ampoule: 1.3 mL

3/10/2026

Opportunity for Comment

Pursuant to 21 CFR 1308.23(e), any interested person may submit written comments on or objections to any chemical preparation in this order that has been approved or denied as exempt. If any comments or objections raise significant issues regarding any finding of fact or conclusion of law upon which this order is based, the Assistant Administrator will immediately suspend the effectiveness of any applicable part of this order until she may reconsider the application in light of the comments and objections filed. Thereafter, the Assistant Administrator shall reinstate, revoke, or amend his original order as she determines appropriate.

Approved Exempt Chemical Preparations Are Posted on DEA's Website

A list of all current exemptions, including those listed in this order, is available on DEA's website at

http://www.DEAdiversion.usdoj.gov/schedules/exempt/exempt_chemlist.pdf.

The dates of applications of all current exemptions are posted for easy reference.

Signing Authority

This document of the Drug Enforcement Administration was signed on May 14, 2026, by DEA Assistant Administrator Cheri Oz. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the

Federal Register

.

Heather Achbach,

Federal Register Liaison Officer, Drug Enforcement Administration.

[FR Doc. 2026-10090 Filed 5-19-26; 8:45 am]

BILLING CODE 4410-09-P